About us
Our team
Our science
Radiopharmaceuticals
Our technology
Abstracts & publications
Our pipeline
News
Investors
Contact us
News
ASX Releases
RAD Invited to Participate in Jefferies Radiopharma Innovation Summit
March 28, 2023
Read more
Read more
RAD Receives $1.56M R&D Tax Incentive
March 28, 2023
Read more
Read more
RAD and GenesisCare Partner to Develop Novel Radiopharmaceuticals in Australia
March 27, 2023
Read more
Read more
RAD to Present at Virtual Healthcare Conference
March 17, 2023
Read more
Read more
Dr Kenn Herrmann appointed to RAD Scientific Advisory Board
March 3, 2023
Read more
Read more
RAD to acquire Pharma15 Corporation
March 3, 2023
Read more
Read more
RAD Initiates Process for Nasdaq Listing
February 14, 2023
Read more
Read more
Dr. Rama Abu Shmeis appointed Senior VP, CMC
January 11, 2023
Read more
Read more
avB6 Integrin (RAD301) IND Approval for Phase 1 Trial
December 29, 2022
Read more
Read more
RAD201 HER2 Nanobody Demonstrates Favourable Tumor Targeting
December 13, 2022
Read more
Read more
Additional Data Released from Brain Metastases Imaging Trial
November 23, 2022
Read more
Read more
RAD Agreement with ANSTO to supply key isotope lutetium-177
November 22, 2022
Read more
Read more
Successful Completion of Retail Entitlement Offer
November 22, 2022
Read more
Read more
Extension of Retail Entitlement Offer
November 8, 2022
Read more
Read more
Update Proposed Issue of Securities
November 8, 2022
Read more
Read more
AGM Attendance 8 Nov 2022
November 8, 2022
Read more
Read more
Notification of Release of Shares from Escrow
November 8, 2022
Read more
Read more
RAD Agreement with Northstar
October 26, 2022
Read more
Read more
Successful Completion of Institutional Entitlement Offer
October 20, 2022
Read more
Read more
Supplementary Prospectus
October 20, 2022
Read more
Read more
Proposed Issue of Securities
October 19, 2022
Read more
Read more
Prospectus 19 Oct 2022
October 19, 2022
Read more
Read more
Entitlement Offer to Raise up to $10M
October 19, 2022
Read more
Read more
Entitlement Offer Presentation
October 19, 2022
Read more
Read more
Update Proposed Issue of Securities
October 19, 2022
Read more
Read more
Pivalate Achieves Positive Phase 2 Data in Brain Mets Trial
October 18, 2022
Read more
Read more
Presentation - Pivalate Achieves Positive Phase 2 Data
October 18, 2022
Read more
Read more
Investor Webinar - Pivalate Positive Phase 2 Data
October 18, 2022
Read more
Read more
NATURE publishes encouraging data on DUNP19 receptor role in cancer growth
October 4, 2022
Read more
Read more
Ga68 - Integrin (RAD301) Selected for Presentation at EANM
September 27, 2022
Read more
Read more
Pivalate Phase II Data to be Presented at October Conference in Barcelona
September 21, 2022
Read more
Read more
RAD and SHIINE Supply Agreement for Cancer Fighting Isotope
September 20, 2022
Read more
Read more
FDA Grants Rare Pediatric Disease Designation for RAD's DUNP19 for Osteosarcoma - revised
September 16, 2022
Read more
Read more
MD Anderson and RAD Launch Joint Venture to Develop Novel Radiopharmaceuticals
September 14, 2022
Read more
Read more
FDA Grants Orphan Drug Status for DUNP19 in Osteosarcoma
September 9, 2022
Read more
Read more
Strategic Agreements with Lantheus and NanoMab
August 4, 2022
Read more
Read more
Radiopharm Extends Agreement with GenesisCare for Australian Prostate Cancer Trial
July 1, 2022
Read more
Read more
Dr Susann Brady-Kalnay appointed to RAD Scientific Advisory Board
June 21, 2022
Read more
Read more
Investor Webinar - CEO and Riccardo Canevari and Dr Susann Brady-Kalnay to discuss promising radiopharmaceutical agent recently added to the RAD Portfolio
June 15, 2022
Read more
Read more
Radiopharm and Isotopia announce supply agreement for Lutetium-177 N.C.A
June 14, 2022
Read more
Read more
Radiopharm Adds Brain Tumor Technology To Portfolio
June 9, 2022
Read more
Read more
Radiopharm Investor Presentation
June 9, 2022
Read more
Read more
Radiopharm appoints Dr Leila Alland as Non-Executive Director
June 6, 2022
Read more
Read more
Industry Leader Vittorio Puppo Joins RAD as COO
June 1, 2022
Read more
Read more
Bioshares Summit 2022 Presentation
May 12, 2022
Read more
Read more
RAD Licenses UCLA Dual Action Antibody
April 4, 2022
Read more
Read more
RAD Dual Action Antibody Investor Deck
April 4, 2022
Read more
Read more
Radiopharm Theranostics Investor Presentation
March 28, 2022
Read more
Read more
Radiopharm signs LOI with GenesisCare to start first trial in Australia
March 23, 2022
Read more
Read more
Hester Larkin appointed as Non-Executive Director
February 2, 2022
Read more
Read more
Radiopharm and TerraPower sign supply agreement for Actinium-225
February 1, 2022
Read more
Read more
RAD Acquires IP ownership of Radiopharmaceutical Nanobodies
January 24, 2022
Read more
Read more
RAD to present at Biotech Showcase
January 10, 2022
Read more
Read more
Radiopharm Expands Management Team with Three Senior Appointments
December 20, 2021
Read more
Read more
Completion of Phase 1 Study in Breast Cancer
December 17, 2021
Read more
Read more
Letter to Shareholders
December 10, 2021
Read more
Read more
RAD's Integrins Technology featured in Cancers Journal
December 8, 2021
Read more
Read more
Dr Hurvitz SAB Appointment
December 6, 2021
Read more
Read more
ASX Investor Presentation 29 Nov 2021
November 29, 2021
Read more
Read more
Radiopharm Theranostics Lists on the ASX After Raising $50M in IPO
November 25, 2021
Read more
Read more
Radiopharm Theranostics’ Trivehexin (AVβ6-Integrin) published in European Journal of Nuclear Medicine
October 13, 2021
Read more
Read more
European Molecular Imaging Meeting (EMIM) RAD301 Abstract
September 21, 2021
Read more
Read more
RAD201 Published in peer reviewed Journal Molecular Pharmaceutics
September 15, 2021
Read more
Read more
Radiopharm raise release FINAL
August 23, 2021
Read more
Read more
RadioPharm and TRIMT
August 17, 2021
Read more
Read more
MEDIA releases
FNN Interview with CEO about RAD's ambition to list on Nasdaq
February 21, 2023
Read more
Read more
Investor Webinar
February 16, 2023
Read more
Read more
RAD CEO interview with Proactive Investors and announcement of Nasdaq listing initiation
February 14, 2023
Read more
Read more
GenesisCare and RAD Partner to Bring World First Novel Radiopharmaceuticals to Australian Cancer Patients
December 1, 2022
Read more
Read more
CEO Interview series with Wholesale Investor
October 6, 2022
Read more
Read more
RAD to Start Prostate Cancer Trial, Interview with Financial News Network
July 8, 2022
Read more
Read more
World Congress Trivehexin Poster Presentation Shows Encouraging Integrin Data
June 28, 2022
Read more
Read more
CEO Riccardo Canevari Updates Investors and Discusses Licensing of a Asset from UCLA
May 18, 2022
Read more
Read more
Radiopharm Theranostics panel discusses latest progress and understanding of the radiopharmaceutical sector
May 9, 2022
Read more
Read more
Radiopharm continues strong progress and recognition of AVβ6-Integrin in Europe
May 6, 2022
Read more
Read more
CEO Riccardo Canevari visits Sydney and discusses the use of radiopharmaceuticals with Financial News Network
April 4, 2022
Read more
Read more
Appointment of Bill Regan to Senior Vice President Regulatory Strategy
March 15, 2022
Read more
Read more
Presentation at Financial News Network Investor Conference Feb 2022
February 24, 2022
Read more
Read more
Paul Hopper speaks to Matt Birney from Bulls N' Bears
February 18, 2022
Read more
Read more
RAD Expands Management Team with VP of Clinical Development Appointed
February 17, 2022
Read more
Read more
Acceleration in Patient Recruitment with AVB6 - Integrin
February 11, 2022
Read more
Read more
Bulls N' Bears Interview
November 29, 2021
Read more
Read more
Radiopharm Theranostics makes its debut on the ASX as it develops its cancer killing technology
November 25, 2021
Read more
Read more
Radiopharm Theranostics’ Founder Paul Hopper’s keynote address at Emerging Small Caps 2021 Summit
November 12, 2021
Read more
Read more
Paul Hopper’s Radiopharm, Artrya pitch investors this week
October 11, 2021
Read more
Read more
Entrepreneur Paul Hopper launches Radiopharm Theranostics following AU$20M Series A
September 17, 2021
Read more
Read more
Radiopharm secures ex Novartis exec as CEO ahead of IPO
September 6, 2021
Read more
Read more
Biotech veteran Paul Hopper taps Bell Potter and Baker Young for Radiopharma Theranostics pre-IPO
August 23, 2021
Read more
Read more
Sign up to our mailing list.
Receive all the latest news from Radiopharm Theranostics.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form. Please fill out all starred fields.